Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

A series of three dose escalating studies were conducted to investigate the ability of the 17 α -hydroxylase/C 17,20 -lyase inhibitor abiraterone acetate, to cause maximum suppression of testosterone synthesis when delivered to castrate and noncastrate males with prostate cancer. Study A was a singl...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2004-06, Vol.90 (12), p.2317-2325
Main Authors: O'Donnell, A, Judson, I, Dowsett, M, Raynaud, F, Dearnaley, D, Mason, M, Harland, S, Robbins, A, Halbert, G, Nutley, B, Jarman, M
Format: Article
Language:English
Subjects:
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Cancer Research
Clinical
Drug Resistance
Epidemiology
Gynecology. Andrology. Obstetrics
Male genital diseases
Medical sciences
Molecular Medicine
Nephrology. Urinary tract diseases
Oncology
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A series of three dose escalating studies were conducted to investigate the ability of the 17 α -hydroxylase/C 17,20 -lyase inhibitor abiraterone acetate, to cause maximum suppression of testosterone synthesis when delivered to castrate and noncastrate males with prostate cancer. Study A was a single dose study in castrate males. Study B was a single dose study in noncastrate males and study C was a multiple dose study in noncastrate males. The drug was given orally in a once-daily dose and blood samples taken to assess pharmacokinetic (PK) parameters and hormone levels in all patients. The study drug was well tolerated with some variability in PKs. Suppression of testosterone levels to
ISSN:0007-0920
1532-1827
DOI:10.1038/sj.bjc.6601879